Andrew Dickinson Sells 2,500 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Key Points

• Andrew Dickinson, the CFO of Gilead Sciences, sold 2,500 shares of the company stock for a total of $295,200, reducing his ownership by 1.57%.
• Gilead Sciences recently reported $2.01 EPS for the last quarter, exceeding analysts' expectations and showing a 1.4% increase in revenue compared to the previous year.
• The company also announced a quarterly dividend of $0.79 per share, with a dividend yield of 2.6%, reflecting a payout ratio of 62.95%.

Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CFO Andrew Dickinson sold 2,500 shares of the firm's stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the completion of the transaction, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Gilead Sciences Price Performance

Shares of GILD traded up $2.70 during mid-day trading on Friday, hitting $120.55. The company's stock had a trading volume of 1,730,715 shares, compared to its average volume of 8,001,867. The firm has a 50-day moving average price of $115.15 and a 200 day moving average price of $110.45. The stock has a market capitalization of $149.58 billion, a price-to-earnings ratio of 24.05, a PEG ratio of 0.81 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a fifty-two week low of $85.60 and a fifty-two week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is 62.95%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at about $25,000. Activest Wealth Management increased its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the period. GoalVest Advisory LLC increased its stake in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $27,000. Finally, Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the first quarter valued at approximately $29,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GILD. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a "sector perform" rating in a research report on Wednesday, October 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a research report on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Finally, UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $118.65.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.